All In Biotech

NDA 022145 · Msd Sub Merck

Isentress Hd

Raltegravir Potassium · Oral

NovelAccelerated approvalPriority review

Last checked: Nov 19, 2026Latest source record: May 18, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Oct 12, 2007

Approved uses

14

Original approval plus efficacy supplements

Registered trials

271

69 Phase 3, 4 recruiting

FAERS reports

16,486

13,706 serious, 1,641 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 16, 2026.

Adult Patients: ISENTRESS and ISENTRESS HD are human immunodeficiency virus integrase strand transfer inhibitors (HIV-1 INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients ( 1 ). Pediatric Patients: ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg ( 1 ). ISENTRESS HD is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients weighing at least 40 kg ( 1 ). Adult Patients: ISENTRESS ® and ISENTRESS ® HD are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients. Pediatric Patients: ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg. ISENTRESS HD is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients weighing at least 40 kg.

Mechanism: Raltegravir is an HIV-1 antiviral drug [see Microbiology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ISENTRESS HD · RALTEGRAVIR POTASSIUM EQ 600MG BASE · TABLET, ORAL · Prescription · TE AB
  • ISENTRESS · RALTEGRAVIR POTASSIUM EQ 400MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Raltegravir" as an intervention, any sponsor and status, largest first.

All 271 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug interaction1,216
  • foetal exposure during pregnancy1,100
  • depression1,018
  • anxiety965
  • pain917
  • emotional distress789
  • maternal exposure during pregnancy750
  • exposure during pregnancy744
  • anhedonia708
  • virologic failure587
  • renal failure558
  • chronic kidney disease548

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
200717
2008449
2009648
2010739
2011611
20121,020
2013936
20141,051
20151,147
20161,312
20171,044
20181,442
20191,491
20201,204
20211,052
2022891
2023695
2024318
2025256
2026162

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Isentress (Raltegravir Potassium)

2024 spending

$113M

Beneficiaries

7,188

53,765 claims

Per beneficiary

$15,684

$33.14 per unit

View as table
YearSpending
2020$188,251,438
2021$164,360,689
2022$146,220,371
2023$130,537,595
2024$112,736,203

Part D: Isentress Hd (Raltegravir Potassium)

2024 spending

$23.0M

Beneficiaries

1,228

11,049 claims

Per beneficiary

$18,746

$33.08 per unit

View as table
YearSpending
2020$30,536,040
2021$29,368,766
2022$28,930,429
2023$26,641,375
2024$23,019,649

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 348 on PubMed

Sponsor: Merck & Co. · Also marketed as Isentress

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.